Overview

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

The Purpose of this study is to evaluate the safety and tolerability, and the biological effects of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4, given intravenously, weekly for 4 weeks in the treatment of patients with advanced malignancies refractory to conventional anti-cancer treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Cancer Research UK

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins